Expert Insights Into What's Hot in Glaucoma

This program will include a discussion of investigational agents and devices not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Glaucoma Can Result in Blindness

Poor Compliance Can Increase Risk of Progression

Problems With Drops vs Risks of Traditional Surgery

Minimally Invasive Surgery Fills Treatment Gap

Minimally Invasive Glaucoma Surgery (MIGS)

Adverse Effects of Traditional Surgical Approaches

MIGS Classified by Mechanism of Action: Trabecular Meshwork

MIGS Classified by Mechanism of Action: Schlemm Canal

MIGS Classified by Mechanism of Action: Suprachoroidal Space

MIGS Classified by Mechanism of Action: Subconjunctival Space

MIGS Used in Combined Procedures

MIGS Standalone or With Cataract Surgery

MIGS Benefits Ophthalmologists and Patients

Controlled Glaucoma Redefined

Complicated Patient Case

Solution for the Complicated Case

MIGS Allows General Ophthalmologists to Do Glaucoma Surgery

Remembering Basic Ocular Anatomy

Choosing Procedures

Matching Patients and Procedures

Multiple Devices Allow Individualized Care

More New Technologies: Hydrus Microstent

More New Technologies: iStent Inject

Safety of MIGS Procedures

Why General Ophthalmologists Should Consider Adding MIGS to Their Practices

Poor Candidates for MIGS

Steps for Incorporating MIGS Into Practice

Tips for Gonioscopy

New Medications: Latanoprostene Bunod

Rho Kinase Inhibitors

Netarsudil/Latanoprost Combination

New Drug Delivery Devices

New Techniques, New Medications, New Devices Mean New Era in Treatment

Incorporate New Options Into Practice

Abbreviations